By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Emergent BioSolutions 

2273 Research Boulevard
Suite 400
Rockville  Maryland  20850  U.S.A.
Phone: 301-795-1800 Fax: 301-795-1899


SEARCH JOBS
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.


Key Statistics


Email:
Ownership: Public

Web Site: Emergent BioSolutions
Employees:
Symbol: EBS
 









Company News
Emergent BioSolutions (EBS) Receives FDA Approval Of Anthrasil, Its Anthrax Immune Globulin, For Use In The Treatment Of Inhalational Anthrax 3/25/2015 7:52:19 AM
Emergent BioSolutions (EBS) Awarded $31 Million Contract For Advanced Development Of Nuthrax, A Next Generation Anthrax Vaccine 3/24/2015 7:20:47 AM
Emergent BioSolutions (EBS) Signs Agreements With Oxford University, GlaxoSmithKline (GSK), And National Institute of Allergy And Infectious Diseases (NIAID) For The Production Of An MVA Ebola Zaire Vaccine Candidate 3/16/2015 7:20:15 AM
Emergent BioSolutions (EBS) And MorphoSys AG Initiate Phase 1 Clinical Study To Evaluate The Novel Oncology Immunotherapeutic MOR209/ES414 For Prostate Cancer 3/9/2015 7:36:00 AM
Emergent BioSolutions (EBS) To Participate In March 2015 Investor Conferences 2/20/2015 7:52:57 AM
Emergent BioSolutions (EBS) Announces Primary Endpoints Met In Pivotal Study Supporting Licensure Of Building 55 2/13/2015 7:41:26 AM
Emergent BioSolutions (EBS) To Release Fourth Quarter And Full Year 2014 Financial Results And Conduct A Conference Call On March 5, 2015 2/12/2015 7:45:59 AM
Emergent BioSolutions (EBS)'s $60 Million Expansion to Double Current Space and Create 158 New Jobs 2/4/2015 6:51:53 AM
Emergent BioSolutions (EBS) Announces Preliminary 2014 Financial Results And Provides 2015 Financial Outlook 1/12/2015 7:16:24 AM
Emergent BioSolutions (EBS) To Participate In January 2015 Investor Conferences 1/7/2015 10:15:38 AM
12345678910...
//-->